- Home
- TWN vs TLSI Comparison
TWN vs TLSI Comparison
Compare TWN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- TLSI
- Stock Information
- Founded
- TWN 1986
- TLSI 2010
- Country
- TWN Hong Kong
- TLSI United States
- Employees
- TWN N/A
- TLSI N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- TLSI Medical Specialities
- Sector
- TWN Finance
- TLSI Health Care
- Exchange
- TWN Nasdaq
- TLSI Nasdaq
- Market Cap
- TWN 193.5M
- TLSI 160.4M
- IPO Year
- TWN N/A
- TLSI N/A
- Fundamental
- Price
- TWN $37.77
- TLSI $5.35
- Analyst Decision
- TWN
- TLSI Strong Buy
- Analyst Count
- TWN 0
- TLSI 5
- Target Price
- TWN N/A
- TLSI $10.90
- AVG Volume (30 Days)
- TWN 20.1K
- TLSI 43.7K
- Earning Date
- TWN 01-01-0001
- TLSI 05-15-2025
- Dividend Yield
- TWN 1.10%
- TLSI N/A
- EPS Growth
- TWN N/A
- TLSI N/A
- EPS
- TWN N/A
- TLSI N/A
- Revenue
- TWN N/A
- TLSI $32,141,000.00
- Revenue This Year
- TWN N/A
- TLSI $55.13
- Revenue Next Year
- TWN N/A
- TLSI $50.71
- P/E Ratio
- TWN N/A
- TLSI N/A
- Revenue Growth
- TWN N/A
- TLSI 46.20
- 52 Week Low
- TWN $25.22
- TLSI $3.50
- 52 Week High
- TWN $41.51
- TLSI $7.75
- Technical
- Relative Strength Index (RSI)
- TWN 72.66
- TLSI 54.12
- Support Level
- TWN $36.61
- TLSI $5.35
- Resistance Level
- TWN $37.47
- TLSI $5.68
- Average True Range (ATR)
- TWN 0.76
- TLSI 0.35
- MACD
- TWN 0.05
- TLSI 0.05
- Stochastic Oscillator
- TWN 91.10
- TLSI 71.79
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.